Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Integrins are a large family of heterodimeric transmembrane receptors, consisting of alpha and beta subunits, that facilitate cell-cell and cell-extracellular matrix (ECM) adhesion (Hynes, 2002, Cell). The ECM components, such as collagen, fibronectin, and laminin, serve as ligands that trigger outside-in signaling pathways regulating cell survival, proliferation, and migration (Humphries et al., 2006, Journal of Cell Science). Conversely, inside-out signaling regulates the affinity of integrins for their ligands, which is crucial for processes like platelet aggregation and leukocyte extravasation (Ley et al., 2016, Nature Reviews Immunology). In disease states, dysregulation of the integrin-ECM axis contributes to tumor metastasis, pathological angiogenesis, chronic inflammation, and fibrotic tissue buildup (Desgrosellier & Cheresh, 2010, Nature Reviews Cancer). Therapeutic strategies often involve monoclonal antibodies or small molecules designed to block specific integrin-ligand interactions, such as those targeting alpha-IIb-beta-3 for anti-thrombotic effects or alpha-4-beta-7 for inflammatory bowel disease (Coller, 2001, JCI).
Inhibition of integrin-mediated cell adhesion and signaling by blocking the interaction between integrin receptors and their extracellular matrix ligands (e.g., fibrinogen, fibronectin, or VCAM-1) (Ley et al., 2016, Nature Reviews Immunology).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Integrins and extracellular matrix components (Integrins/ECM).